TACE has been the standard of care for intermediate-stage hepatocellular carcinoma, but EBRT has emerged as a potential noninvasive alternative. Researchers conducted a meta-analysis of ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...